Ezekiel Adewale, DO
Hospitalist · Media, PANPI 1225463920
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $8,130 of the $11,440 with a category attached, or 71.1%. Gilead accounts for 85.8% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $7,890 and has fallen 95.3% since, to $369 in 2025. Among hospitalist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 100 payments — averaging $114.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$10K
- Novartis$253
- AbbVie$252
- Novo Nordisk$162
- Pfizer$116
- AstraZeneca$95
- plus $744 from 18 others
What the payments were for
- Speaking & faculty fees$8,13071%
- Travel & lodging$1,18110%
- Food & beverage$2,12819%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 16 | $9,818 |
| Novartis | 14 | $253 |
| AbbVie | 13 | $252 |
| Novo Nordisk | 8 | $162 |
| Pfizer | 6 | $116 |
| AstraZeneca(2 entities) | 5 | $95 |
| Lilly USA, LLC | 5 | $89 |
| Astellas Pharma US Inc | 3 | $72 |
| Bayer | 4 | $69 |
| Dexcom, Inc. | 2 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Amgen | 3 | $58 |
| Sanofi Pasteur Inc. | 3 | $57 |
| Merck | 2 | $41 |
| Boehringer Ingelheim | 2 | $31 |
| GSK | 2 | $31 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $30 |
| Exact Sciences | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Corium, LLC | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Lundbeck LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veklury$9,670
How this compares
$11,440 in reported general payments places this provider in the 95th percentile of 1,287 hospitalist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 27 | $18,518 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $1,493 |
| Celecoxib | 13 | $1,020 |
| Naloxone Hcl | 11 | $754 |
| Rosuvastatin Calcium | 15 | $481 |
| Midodrine Hcl | 11 | $265 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 11 | $258 |
| Tamsulosin Hcl | 21 | $241 |
| Metoprolol Succinate | 34 | $236 |
| Fluticasone Propionate | 28 | $225 |
| Atorvastatin Calcium | 18 | $189 |
| Ropinirole Hcl | 18 | $187 |
| Amlodipine Besylate | 43 | $170 |
| Pantoprazole Sodium | 24 | $149 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 19 | $149 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $116 | $18,51827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,287 hospitalist providers in Pennsylvania.
Other hospitalist in Media
- Khalid AhmedPhiladelphia$55K
- Umang PatelLanghorne$21K
- Irfan AhsanPhiladelphia$21K
- Kevin VolppPhiladelphia$17K
- Amanulla KhajiWynnewood$15K
- Maria DrosouWynnewood$15K
- Jeffrey GindiWilkes Barre$13K
- Joseph SabolPittsburgh$12K
- Matthew DemczkoPhiladelphia$11K
- Sohrab KhaladjPittsburgh$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.